Mizuho lowered the firm’s price target on Autolus Therapeutics to $12 from $18 and keeps a Buy rating on the shares following the Q4 results. The reduced price target reflects dilution from the stock offering in Q4 and the positive offset of raising obe-cel’s probability of success to 80% from 70%, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AUTL:
- Autolus Therapeutics reports FY22 EPS ($1.57), consensus ($1.58)
- Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
- Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
- Biotech Alert: Searches spiking for these stocks today
- 2 “Strong Buy” Penny Stocks That Could Rally All the Way to $11 (or More)
